We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
We are investigating experimental medications for both Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC) accounts for about 85–90% of Lung Cancer diagnoses, while Small cell lung cancer (SCLC) is composed of 10-15% of Lung Cancer diagnoses. These two types of cancer differ in how they grow and how they spread.
Answer a few questions below to see if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
Lung cancer has been the most common cancer in the world for several decades, and despite advancements in treatment, has resulted in more deaths than any other cancer.
Learn MoreBristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information